Disposition of ropinirole in animals and man.
1. The disposition and metabolic fate of ropinirole, a novel compound indicated for the symptomatic treatment of Parkinson's disease, was studied in the mouse, rat, cynomolgus monkey and man, following oral and intravenous administration of ropinirole hydrochloride. 2. In all species, nearly all of the p.o. administered dose (94%) was rapidly absorbed from the gastrointestinal tract following administration of 14C-ropinirole hydrochloride. In rat and monkey, the compound distributed rapidly beyond total body water and was shown to cross the blood-brain barrier. Blood clearance of the compound was high, approximately equal to one-half the hepatic blood flow in the monkey and similar to the hepatic blood flow in rat. Terminal phase elimination half-lives for the compound were relatively short (0.5 and 1.3 h in rat and monkey respectively), although there was evidence of a second elimination phase in the monkey with an elimination half-life of approximately 5-11 h. Plasma concentrations of ropinirole after the intravenous dose were not determined in the mouse and were below the lower limit of quantification in man (0.08 ng/ml) at the doses used in the studies described in this paper. 3. In both animals and man, ropinirole was extensively metabolized. In the rat, the major metabolic pathway was via hydroxylation of the aromatic ring to form 7-hydroxy ropinirole. In mouse, monkey and man, the major pathway was via N-depropylation. The N-despropyl metabolite was metabolized further to form 7-hydroxy and carboxylic acid derivatives. Metabolites formed in all species were generally metabolized further by glucuronidation. 7-Hydroxy ropinirole is the only metabolite of ropinirole previously shown to possess significant dopamine agonist activity in vivo. In all species, the major route of excretion of ropinirole-related material after oral or intravenous administration of the compound was renal (60-90% of dose).
Ramji
J V
JV
Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, Welwyn, UK. Jayant_Ramji@sbphrd.com
Keogh
J P
JP
Blake
T J
TJ
Broom
C
C
Chenery
R J
RJ
Citerone
D R
DR
Lewis
V A
VA
Taylor
A C
AC
Yeulet
S E
SE
D000042:Absorption; D000328:Adult; D000818:Animals; D000978:Antiparkinson Agents / Q000378:metabolism* / Q000493:pharmacokinetics; D002250:Carbon Radioisotopes; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000378:metabolism* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D006801:Humans; D007211:Indoles / Q000378:metabolism* / Q000493:pharmacokinetics; D008252:Macaca fascicularis; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008875:Middle Aged; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values; D013045:Species Specificity; D014018:Tissue Distribution
D000978:Antiparkinson Agents; D002250:Carbon Radioisotopes; D018491:Dopamine Agonists; D007211:Indoles; C046649:ropinirole; D004298:Dopamine